- 6 Dec 2018
Stada said Thursday it increases its indirect shareholding in the Vietnamese pharmaceutical company Pymepharco JSC to 72 percent, with a goal to expand in the one of the key growth markets in Asia.
- 4 Dec 2018
Gilead’s company Kite’s trial for KTE-X19, its chimeric antigen receptor T cell therapy for adults with ALL (leukemia), resulted in high number of patients getting complete leukemia remission after a single infusion.
- 4 Dec 2018
Bristol-Myers Squibb will transfer $3.8 billion of U.S. pension obligations through a full termination of its U.S. Retirement Income Plan. BMS said it will distribute the obligations through a combination of lump sums to Plan participants who elect such payments, and the purchase of a group annuity contract from Athene
- 3 Dec 2018
AstraZeneca will divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal for uprfont payments of $815 million.
- 3 Dec 2018
Novartis’s Biologics License Application (BLA) for Zolgensma, designed to tackle the genetic root cause of spinal muscular atrophy (SMA) Type 1, a deadly neuromuscular disease, was accepted by the U.S. Food and Drug Administration (FDA).
- 3 Dec 2018
Swiss Helsinn Group and Mundipharma China Pharmaceutical will now sell ALOXI IV in China, as it got approval from the National Medical Products Administration (NMPA), which is the first Helsinn cancer supportive care in China, which will be mareketed by Mundipharma China Pharmaceutical.
- 3 Dec 2018
Shield Therapeutics said Monday that US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead product Feraccru.
- 3 Dec 2018
Tiziana Life Sciences has completed patient enrollment in the ongoing Phase 2a clinical a single-arm, repeated-dose, 6-month duration study of Milciclib for certain patients with unresectable or metastatic HCC, with the topline data from this multi-center trial, being conducted in Italy, Greece and Israel, will be available in the second quarter of 2019.
My Pharmaceutical
Consequences of microbead: What makes microbeads problematic
In the world of great discoveries that cure or add a positive element to our everyday existence, the invention of microbeads hasn’t proven to be one of them. Not alone in its quick rise to popularity and slow journey to extinction, the microbead is just one of numerous products rushed to market before its long term effects are uncovered. In the field of medicine, for instance, at least 35 drugs have been banned by the FDA – many long after they were approved and commonly prescribed. The same is true for the microbead, born from the development of thermoplastics, a result of the scarcity of natural rubber at the beginning of World War II. Found to have a multitude of commercial applications, the ingredient was quickly added to the formulation of cosmetic products.
